|
A Study of Dato-DXd in Participants With Solid Tumors [TROPION-PanTumor04 (TP04)]
RECRUITINGPhase 1/2Sponsored by Daiichi Sankyo
Actively Recruiting
PhasePhase 1/2
SponsorDaiichi Sankyo
Started2026-10-16
Est. completion2029-09-30
Eligibility
Age18 Years+
Healthy vol.Accepted
View on ClinicalTrials.gov →
NCT07890714
Summary
This clinical trial is designed to assess the safety, tolerability, and antitumor activity of Datopotamab Deruxtecan (Dato-DXd) combined with other anticancer agents or as monotherapy in participants with solid tumors.
Eligibility
Age: 18 Years+Healthy volunteers accepted
Key Inclusion Criteria: 1. Must consent to provide archival tumor tissue sample or newly obtained pretreatment biopsy if clinically feasible and at an acceptable risk as determined by the investigator. 2. Eastern Cooperative Oncology Group (ECOG) performance status (PS) score of 0 or 1 assessed no more than 14 days prior to Cycle 1 Day 1 (C1D1) (randomization for randomized cohort). 3. Has adequate organ and bone marrow function as assessed by local laboratory within 7 days prior to C1D1 (randomization for randomized cohort) as defined in the protocol. 4. Has a left ventricular ejection fraction (LVEF) ≥50 percent (%) by either an echocardiogram (ECHO) or multigated acquisition scan (MUGA) scan within 28 days before C1D1 (randomization for randomized cohort). 5. Has a life expectancy ≥3 months based on investigator's assessment. 6. Female participants must not be pregnant, does not plan to breastfeed during the trial intervention period, agrees to adhere to a contraceptive method that is highly effective and agrees not to donate eggs (ova, oocytes) to others or freeze/store eggs during the intervention period. 7. Male participants who intend to be sexually active with a female partner of childbearing potential should use additional barrier methods of contraception or avoid intercourse. Male participants must not freeze or donate sperm at any time during this study. Key Exclusion Criteria: 1. Has unresolved toxicities from previous anticancer therapy. 2. Has spinal cord compression or clinically active central nervous system (CNS) metastases. 3. Has a history of severe hypersensitivity reactions to either the drug substances or inactive ingredients. 4. Has uncontrolled or significant cardiovascular disease. 5. Has a history of non-infectious interstitial lung disease (ILD)/pneumonitis, including radiation pneumonitis that required steroids, has current ILD/pneumonitis, or has suspected interstitial lung disease (ILD)/pneumonitis that cannot be ruled out by imaging at screening. 6. Has clinically severe pulmonary function compromise resulting from intercurrent pulmonary illnesses. 7. Has clinically significant corneal disease. 8. Evidence of ongoing uncontrolled systemic bacterial, fungal, or viral infection. 9. Has active or uncontrolled HIV infection. 10. Has active or uncontrolled hepatitis B or C virus infection. 11. Female participants who are pregnant or breastfeeding or intend to become pregnant. 12. Live vaccines within 30 days before the first dose of treatment.
Conditions4
CancerLung CancerNon Small Cell Lung CancerUrothelial Cancer
Interventions4
Related trials
- A Study to Explore Safety, Tolerability, Pharmacokinetics, and Anti-tumor Activity of Novel Therapeutics in Patients With Early Relapsed Metastatic Triple-negative Breast Cancer — Gustave Roussy, Cancer Campus, Grand Paris
- A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer (TROPION-Breast05) — AstraZeneca
- An Open-label Study to Investigate the Efficacy and Safety of Dato-DXd + Rilvegostomig vs SoC in Adult Participants With High-risk MIUC — AstraZeneca
- Neoadjuvant and Adjuvant Treatment in Resectable Non-small Cell Lung Cancer — AstraZeneca
- Study of Datopotamab Deruxtecan Plus Carboplatin or Cisplatin Versus Gemcitabine Plus Carboplatin or Cisplatin in Participants With Locally Advanced or Metastatic Urothelial Carcinoma — Daiichi Sankyo
- A Study of Novel Combinations in Non-Small Cell Lung Cancer (NSCLC) — AstraZeneca
- A Study of Dato-DXd in Inoperable or Metastatic Hormone Receptor-positive, HER2 IHC 0 Breast Cancer — AstraZeneca
- A Study of Ivonescimab in Combination With Dato-DXd or Osimertinib in People With Non-Small Cell Lung Cancer — Memorial Sloan Kettering Cancer Center
Browse More Trials
Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.
This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.
Actively Recruiting
PhasePhase 1/2
SponsorDaiichi Sankyo
Started2026-10-16
Est. completion2029-09-30
Eligibility
Age18 Years+
Healthy vol.Accepted
View on ClinicalTrials.gov →
NCT07890714